Neumora Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Neumora Therapeutics, Inc. (NASDAQ: NMRA) is a clinical-stage biopharmaceutical company focused on redefining neuroscience drug development through a precision medicine approach. By integrating data science and neuroscience, Neumora aims to develop targeted therapies for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. Following the clinical failure and subsequent discontinuation of its lead asset, navacaprant, the company's pipeline is anchored by NMRA-511 (targeting Alzheimer's disease agitation), NMRA-898 (a muscarinic M4 receptor positive allosteric modulator for schizophrenia), and NMRA-215 (a brain-penetrant NLRP3 inhibitor for cardiometabolic disease).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the Phase 3 failures of navacaprant in major depressive disorder, Neumora is discontinuing navacaprant development and pivoting its clinical focus entirely to its remaining pipeline: NMRA-511 (Alzheimer's disease agitation), NMRA-898 (schizophrenia), and NMRA-215 (cardiometabolic disease/obesity).
Expected impact: Focuses capital and clinical infrastructure on potential best-in-class assets with distinct biological mechanisms.
Implementing a workforce reduction of approximately 35% to align the organizational structure with the refocused clinical pipeline.
Expected impact: Expected to generate approximately $10 million in annualized cost savings, extending the cash runway into the third quarter of 2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating on neuroscience discovery, development, and commercialization by applying Neumora's precision neuroscience platform to insights from Amgen's deCODE genetics and human data research capabilities. Neumora also acquired exclusive global rights to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase.
Terms: Includes a $100 million equity investment from Amgen in Neumora.